The Outcome Reduction with an Initial Glargine Intervention ( ORIGIN ) trial randomised @,@ people with diabetes , impaired glucose tolerance or impaired fasting glucose to receive standard glycaemic care or standard care with the addition of basal insulin glargine ( A@Gly , B@Arg , B@Arg human insulin ) , targeting a fasting plasma glucose level @ mmol/l .